A client with Alzheimer's disease is being treated with the medication Exelon. The nurse knows that this drug is also used to treat which disorder?

A. Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system. Treatments for MS focus on modifying the disease course and managing symptoms, including interferon beta, glatiramer acetate, natalizumab, fingolimod, and symptomatic therapies like muscle relaxants or antispasticity medications. Exelon (rivastigmine) has no role in treating MS because it does not affect immune modulation or demyelination. B. “None of the above” is not correct because Exelon is used in another neurologic condition besides Alzheimer’s disease. Specifically, it is approved for dementia associated with Parkinson’s disease, making this choice inaccurate. C. Exelon (rivastigmine) is a cholinesterase inhibitor that works by preventing the breakdown of acetylcholine, thereby increasing its availability in the brain. This is beneficial in Parkinson’s disease dementia (PDD), which can develop in patients with Parkinson’s disease as a result of dopaminergic and cholinergic deficits in the CNS. By improving cholinergic function, rivastigmine can help enhance cognition, attention, and some behavioral symptoms such as apathy or mild agitation. Nurses should be aware that rivastigmine is not a cure, but it may slow the progression of cognitive symptoms and improve quality of life in both Alzheimer’s disease and PDD. D. Exelon is not an antiepileptic drug and does not act on neuronal excitability to prevent seizures. Its mechanism of action is specific to cholinergic neurotransmission, so it does not treat seizure disorders.